Efp as a new molecular target for breast cancer therapy

Anti-Cancer Drugs

Volumn 14, Issue 1, 2003, Pages 1-2

  Horie, Kuniko ^a   Urano, Tomohiko ^b   Inoue, Satoshi ^a,b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BRCA1 PROTEIN; BRCA2 PROTEIN; HORMONE; HORMONE RECEPTOR; LETROZOLE; PROTEASOME; PROTEIN; PROTEIN EFP; RALOXIFENE; RETINOIC ACID RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UBIQUITIN; UNCLASSIFIED DRUG;

BINDING SITE; BREAST CANCER; CANCER HORMONE THERAPY; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; DNA LIBRARY; DOWN REGULATION; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; GENOME; HUMAN; NOTE; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FOLDING; STROKE; VAGINA BLEEDING; VEIN THROMBOSIS;

ANIMALS; BREAST NEOPLASMS; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; FEMALE; GENE THERAPY; HUMANS; TRANSCRIPTION FACTORS;

EID: 0037265128     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200301000-00001     Document Type: Note

References (10)

1. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J Am Med Ass 1999; 281:2189-2197.
2. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-2258.
3. Inoue S, Orimo A, Hosoi T, Kondo S, Toyoshima H, Kondo T, et al. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci USA 1993; 90:11117-11121.
4. Orimo A, Inoue S, Ikeda K, Muramatsu M. MoLecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localization with estrogen receptor mRNA in target organs. J Biol Chem 1995; 270:24406-24413.
5. Ikeda K, Orimo A, Higashi Y, Muramatsu M, Inoue S. Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett 2000; 472:9-13.
6. Orimo A, Inoue S, Minowa O, Tominaga N, Tomioka Y, Sate M, et al. Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor. Proc Natl Acad Sci USA 1999; 96:12027-12032.
7. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, et al. Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature 2002; 417:871-875.
8. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401:616-620.
9. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe V, et al. Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells. Cancer Res 2001; 61:76-80.
10. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3σ (stratifin) is an early event in breast cancer. Oncogene 2001; 20:3348-3353.